{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:20Z","timestamp":1753892000291,"version":"3.41.2"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073328"],"award-info":[{"award-number":["82073328"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>We aimed to evaluate the efficacy and feasibility of concurrent weekly docetaxel-nedaplatin and hypo-fractionated radiotherapy (hypo-RT) in atypical histologic subtypes of primary and metastatic mediastinal malignancies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Fifty-four patients diagnosed with atypical primary or metastatic mediastinal malignancies were retrospectively reviewed. 30 patients received concurrent weekly docetaxel and nedaplatin and hypo-RT (CChRT group) and 24 patients had hypo-RT alone (hRT group). Overall response rate (ORR), in-field locoregional progression-free survival (LPFS) and toxicities were analyzed. The radiobiological effect was evaluated by the LQRGC\/TCP model, incorporating four \u201cR\u201ds of radiobiology, Gompertzian tumor growth and radio-sensitizing effect of chemotherapeutic agent. The biologically effective doses (BEDs) were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median follow-up time was 29.2 months for all patients. The ORR was 86.7% in CChRT group, compared with 62.5% in hRT group (<jats:italic>p<\/jats:italic>=0.033). The 2-year in-field LPFS of CChRT and hRT group was 73.4% and 47.3%, respectively (<jats:italic>p<\/jats:italic>=0.003). There was no significant difference of any &amp;gt;=Grade 3 toxicities between the two groups (<jats:italic>p<\/jats:italic>=0.754). The mean total dose and mean BED by the LQRGC\/TCP model in CChRT group were 58.2Gy and 72.34Gy, versus 52.6Gy and 67.25Gy in hRT group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Concurrent weekly docetaxel-nedaplatin and hypo-RT achieved promising in-field LPFS and tolerable toxicities compared with hypo-RT alone in different histologic subtypes of primary and metastatic mediastinal malignancies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.974394","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T06:02:58Z","timestamp":1665122578000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the efficacy and feasibility of concurrent weekly docetaxel-nedaplatin and hypo-fractionated radiotherapy in atypical histologic subtypes of primary and metastatic mediastinal malignancies"],"prefix":"10.3389","volume":"12","author":[{"given":"FanJun","family":"Meng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XinLei","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DaQuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FangJie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NaiBin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JinYu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XiaoYan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ShaoHan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.02.003","article-title":"Inoperable pulmonary carcinoid tumors: Local control rates with stereotactic body Radiotherapy\/Hypofractionated RT with image-guided radiotherapy","volume":"20","author":"Singh","year":"2019","journal-title":"Clin Lung Cancer."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30242","article-title":"Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck","volume":"122","author":"Chau","year":"2016","journal-title":"Cancer."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198708000-00009","article-title":"Primary malignant mediastinal germ-cell tumors and the contribution of radiotherapy: a southeastern multi-institutional study","volume":"10","author":"Kersh","year":"1987","journal-title":"Am J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13014-019-1317-x","article-title":"Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up","volume":"14","author":"Parisi","year":"2019","journal-title":"Radiat Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11646","article-title":"Hypofractionated accelerated chemo-radiotherapy (Chemo-HypoAR) with cisplatin and liposomal doxorubicin for the treatment of patients with uterine sarcomas","volume":"33","author":"Domoxoudis","year":"2019","journal-title":"In Vivo"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(92)90726-X","article-title":"Hypofractionated accelerated radiotherapy in osteogenic sarcoma","volume":"24","author":"Lombardi","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s003840050048","article-title":"Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study","volume":"11","author":"Skarlatos","year":"1996","journal-title":"Int J Colorect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/0360-3016(92)90382-R","article-title":"Synergistic effects of taxol\/taxotere on radiation sensitivity on human tumor cell lines","volume":"24","author":"Choy","year":"1992","journal-title":"Int J Radiat OncologyBiologyPhysics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.radonc.2021.11.033","article-title":"Comparison and quantification of different concurrent chemotherapy regimens with radiotherapy in locally advanced non-small cell lung cancer: Clinical outcomes and theoretical results from an extended LQ and TCP model","volume":"167","author":"Ai","year":"2021","journal-title":"Radiother Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.10.035","article-title":"Docetaxel and nedaplatin twice a week with concurrent definitive radiotherapy in inoperable esophageal squamous cell carcinoma: A phase I trial (GASTO-1021)","volume":"155","author":"Chen","year":"2021","journal-title":"Radiother Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/01.coc.0000182440.11653.5f","article-title":"Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer","volume":"28","author":"Koukourakis","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.lungcan.2021.04.020","article-title":"Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017)","volume":"156","author":"Chen","year":"2021","journal-title":"Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2021.06.004","article-title":"Hypofractionated intensity modulated radiation therapy with concurrent chemotherapy in locally advanced non-small cell lung cancer: A phase II prospective clinical trial (GASTO1011)","volume":"11","author":"Qiu","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13014-020-01704-2","article-title":"Developing and validating an integrated gross tumor volume (GTV)-TNM stratification system for supplementing unresectable locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy","volume":"15","author":"Chen","year":"2020","journal-title":"Radiat Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.radonc.2019.03.035","article-title":"Comparison of hyper- and hypofractionated radiation schemes with IMRT technique in small cell lung cancer: Clinical outcomes and the introduction of extended LQ and TCP models","volume":"136","author":"Li","year":"2019","journal-title":"Radiother Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13014-020-01555-x","article-title":"Investigating the loco-regional control of simultaneous integrated boost intensity-modulated radiotherapy with different radiation fraction sizes for locally advanced non-small-cell lung cancer: clinical outcomes and the application of an extended LQ\/TCP model","volume":"15","author":"Qiu","year":"2020","journal-title":"Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/61\/10\/3903","article-title":"An analysis of tumor control probability of stereotactic body radiation therapy for lung cancer with a regrowth model","volume":"61","author":"Tai","year":"2016","journal-title":"Phys Med Biol"},{"volume-title":"Perez & brady\u2019s principles and practice of radiation oncology","year":"2019","author":"Halperin","key":"B18"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00330","article-title":"Radiotherapy for thymic carcinoma: adjuvant, inductive, and definitive","volume":"3","author":"Komaki","year":"2014","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.08.133","article-title":"Chemoradiotherapy for unresectable cases of thymic epithelial tumors: A retrospective study","volume":"9","author":"Kashima","year":"2017","journal-title":"J Thorac Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0360-3016(98)00073-X","article-title":"Role of radiation therapy in the treatment of primary tracheal carcinoma","volume":"41","author":"Mornex","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B23","article-title":"Biological basis of radiation sensitivity. part 2: Cellular and molecular determinants of radiosensitivity","volume":"14","author":"Rosen","year":"2000","journal-title":"Oncol (Williston Park)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.03.005","article-title":"Role of cell cycle in mediating sensitivity to radiotherapy","volume":"59","author":"Pawlik","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1748-717X-3-36","article-title":"Normal tissue toxicity after small field hypofractionated stereotactic body radiation","volume":"3","author":"Milano","year":"2008","journal-title":"Radiat Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.4675","article-title":"Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice","volume":"32","author":"Timmerman","year":"2014","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3978\/j.issn.2072-1439.2014.01.14","article-title":"Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy","volume":"6","author":"Prasanna","year":"2014","journal-title":"J Thorac Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3186","article-title":"Accelerated hypofractionated image-guided vs conventional radiotherapy for patients with stage II\/III non-small cell lung cancer and poor performance status: A randomized clinical trial","volume":"7","author":"Iyengar","year":"2021","journal-title":"JAMA Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/030089161309900405","article-title":"Efficacy and safety of concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced nasopharyngeal cancers","volume":"99","author":"Baykara","year":"2013","journal-title":"Tumori"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181a5275c","article-title":"A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC)","volume":"4","author":"Jain","year":"2009","journal-title":"J Thorac Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.974394\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T06:03:05Z","timestamp":1665122585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.974394\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":30,"alternative-id":["10.3389\/fonc.2022.974394"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.974394","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"article-number":"974394"}}